This product is an ASHP Learning Center https://elearning.ashp.org/ activity.
Accreditation
The American Society of Health-System Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education with Commendation.
Target Audience
This professional certificate is intended for pharmacists who have an interest in learning more about the basics of oncology treatment and patient care.
Overview
The Basics of Oncology in Pharmacy Certificate provides the information health-system pharmacists need to know about the most commonly seen oncology concerns. Starting with the language used within oncology and reviewing the oncology treatments, a learner will refresh and update their knowledge on current practice guidelines. Additionally, supportive care, financial considerations, and evaluating advances as they emerge in the literature will be covered. To complete their learning experience, learners will apply their new knowledge through multifaceted patient cases on breast cancer, prostate cancer, and hematologic malignancy management.
Basics of Oncology Certificate Requirement
Once a learner has completed the educational curriculum, they will have the opportunity to complete an online comprehensive exam. Once the learner completes the exam (minimum 80% passing rate; unlimited attempts permitted), they will earn the professional certificate.
Educational Activities
Oncology Pharmacy Fundamentals
ACPE #: 0204-0000-25-784-H01-P
Application-based
1.5 contact hours
Learning Objectives:
- Explain fundamental concepts of cancer pathophysiology.
- Interpret common nomenclature as it related to the diagnosis and treatment of cancer.
- Identify principles of cancer treatment.
- Categorize systemic cancer therapies based on mechanism of action.
Oncology Treatment Basics: Traditional Chemotherapy
ACPE #: 0204-0000-25-785-H01-P
Application-based
2.25 contact hours
Learning Objectives:
- Design supportive care plans for patients receiving traditional antineoplastics.
- Select appropriate monitoring parameters for patients receiving traditional antineoplastics.
- Contrast the toxicity profile of traditional and liposomal or non-conventional antineoplastic agents.
- Identify patients at risk for increased toxicity due to organ dysfunction or drug interactions.
Oncology Treatment Basics: Targeted Agents and Hormonal Therapies
ACPE #: 0204-0000-25-786-H01-P
Application-based
3 contact hours
Learning Objectives:
- Predict “on target” toxicity profile of targeted antineoplastics based on agent’s target.
- Design care plans for managing adverse drug reactions of targeted antineoplastics.
- Analyze drug-drug interactions with targeted agents.
- Compare hormonal-based therapies commonly used in the treatment of breast and prostate cancer.
Oncology Treatment Basics: Immunotherapies and Stem Cell Transplant
ACPE #: 0204-0000-25-787-H01-P
Application-based
2.75 contact hours
Learning Objectives:
- Compare the mechanism of action, indications, and clinical pearls of immune checkpoint inhibitors, chimeric antigen receptor T-cell (CAR-T) therapies, tumor-infiltrating lymphocytes (TILS), and bispecific T-cell engager (BiTE) therapies.
- Assess logistical and dispensing considerations for the administration of immunotherapies.
- Given a patient case, choose an appropriate supportive care and monitoring plan for patients receiving immunotherapies.
- Summarize the pharmacology and non-hematologic dose dose-limiting toxicities of chemotherapy agents commonly used in hematopoietic stem cell transplantation (HCT) conditioning regimens.
- Differentiate between myeloablative, reduced-intensity, and non-myeloablative conditioning regimens.
- Identify strategies for the prevention and treatment of graft-versus-host disease (GVHD).
- Outline treatment goals for short- and long-term monitoring plans for patients with hematologic malignancies.
Supportive Care for the Oncology Patient, Part 1
ACPE #: 0204-0000-25-788-H01-P
Application-based
2.5 contact hours
Learning Objectives:
- Evaluate oncologic agents that are at high risk for infusion reactions to determine appropriate reaction management.
- Analyze risk factors for tumor lysis syndrome.
- Choose appropriate therapy for patients presenting with tumor lysis syndrome.
- Describe the pathophysiology and types of chemotherapy-induced nausea and vomiting (CINV).
- Compare antiemetic agents available for the treatment and prevention of CINV.
- Given a patient case, design an appropriate antiemetic regimen for the treatment of refractory CINV.
- Compare the mechanism of action, indications, dosing, and clinical pearls of anti-resorptive therapies in oncology.
- Given a patient case, choose the most appropriate anti-resorptive treatment regimen for an oncology patient.
Supportive Care for the Oncology Patient, Part 2
ACPE #: 0204-0000-25-789-H01-P
Application-based
2.75 contact hours
Learning Objectives:
- Compare available medications for the treatment of myeloid suppression related to cancer therapies.
- Given a patient case, develop an appropriate treatment regimen for a patient with febrile neutropenia.
- Given a patient case, choose an appropriate growth factor regimen for the treatment of myeloid suppression related to cancer therapies.
- Differentiate between the grades of Cytokine Release Syndrome (CRS) and Immune effector cell-associated neurotoxicity syndrome (ICANS).
- Choose an appropriate treatment plan for patients experiencing Cytokine Release Syndrome (CRS) and Immune effector cell-associated neurotoxicity syndrome (ICANS).
- Describe the pathophysiology of immunotherapy-related adverse events.
- Choose appropriate management strategies for immunotherapy-related adverse events.
Oncology Pharmacy Operations and Logistics
ACPE #: 0204-0000-25-790-H01-P
Application-based
4 contact hours
Learning Objectives:
- Categorize medications based on hazardous risk potential.
- Explain tactics to minimize employee exposure to hazardous drugs.
- Evaluate policies and procedures related to clinical review of parenteral anti-cancer therapies.
- Analyze accuracy of parenteral anti-cancer therapies.
- Evaluate policies and procedures related to clinical review of parenteral anti-cancer therapies.
- Analyze accuracy of parenteral anti-cancer therapies.
- Identify how payer mandates can impact access to care in the changing landscape of oncology.
- Evaluate financial considerations and barriers to medication access as they relate to cancer treatment.
- Interpret the role of the oncology pharmacist into the interdisciplinary care team using pharmacy practice standards.
- Recommend best practice strategies in the management of patients on oral oncolytic therapies.
- Assess the types of trials utilized in oncology drug development.
- Evaluate oncology trials with respect to trial design, sources of bias, endpoints utilized, and applicability to practice.
- Interpret the results of oncology clinical trials for application in clinical practice.
Practical Application of Oncology Pharmacy Concepts
ACPE #: 0204-0000-25-791-H01-P
Application-based
2.5 contact hours
Learning Objectives:
- Develop strategies for managing treatment complications in patients receiving treatment for early-stage breast cancer.
- Recommend a plan for incorporating new study data into clinical practice.
- Given a patient case, choose an appropriate treatment regimen for a patient with prostate cancer.
- Assess the treatment regimen for a patient with prostate cancer to ensure appropriate dispensing, supportive care, and monitoring.
- Design supportive care and monitoring plans for prevention of post-transplant complications.
- Create short- and long-term monitoring plans for patients with hematologic malignancies.
Faculty Information
Danielle Backers, PharmD
Clinical Pharmacist, Markey Access and Innovation Center
University of Kentucky Healthcare – Markey Cancer Center
Lexington, Kentucky
John Bossaer, PharmD, BCOP
Professor
East Tennessee State University - Bill Gatton College of Pharmacy
Johnson City, Tennessee
Allison Butts, PharmD, BCOP
Pharmacy Manager, Oncology
UK HealthCare - Markey Cancer Center
Lexington, Kentucky
Brette Conliffe, PharmD, BCOP, DPLA
Oncology Clinical Supervisor
UofL Health - Brown Cancer Center
Louisville, Kentucky
Raj Duggal, PharmD, BCOP
Clinical Manager - Oncology Pharmacy Services
Indiana University Health – Simon Comprehensive Cancer Center
Indianapolis, Indiana
Lindsay Figg, PharmD, BCOP, DPLA
Clinical Pharmacy Specialist
UofL Health
Louisville, Kentucky
Alixandra Mann, PharmD, BCOP
Hematology/Oncology Clinical Pharmacy Specialist
UofL Health – Brown Cancer Center
Louisville, Kentucky
Katlyn Mulhall, PharmD, BCOP
Hematology/Oncology Clinical Pharmacy Specialist
UofL Health - Brown Cancer Center
Louisville, Kentucky
Ayodele Okunrinboye, PharmD
Hematology and Bone Marrow Transplant Clinical Pharmacist
Indiana University Health Academic Health Center
Indianapolis, Indiana
Logan Roberts, PharmD, BCOP, BCPS
Hematology/Oncology Clinical Pharmacist
UofL Health - Brown Cancer Center
Louisville, Kentucky
Relevant Financial Relationship Disclosure
In accordance with our accreditor’s Standards of Integrity and Independence in Accredited Continuing Education, ASHP requires that all individuals in control of content disclose all financial relationships with ineligible companies. An individual has a relevant financial relationship if they have had a financial relationship with an ineligible company in any dollar amount in the past 24 months and the educational content that the individual controls is related to the business lines or products of the ineligible company.
An ineligible company is any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. The presence or absence of relevant financial relationships will be disclosed to the activity audience.
The following person in control of this activity’s content has relevant financial relationships:
- Lindsay Figg, PharmD, BCOP, DPLA
- Janssen/PrecisionAQ: Advisory Board
- Sanofi/JADPRO: Advisory Board
All other persons in control of content do not have any relevant financial relationships with an ineligible company.
As defined by the Standards of Integrity and Independence in Accredited Continuing Education definition of ineligible company. All relevant financial relationships have been mitigated prior to the CE activity.
Methods and CE Requirements
Each activity consists of audio, video, and/or PDFs and evaluations. Learners must review all content and complete the evaluations to receive continuing pharmacy education credit for each activity.
Follow the prompts to claim, view, or print the statement of credit within 60 days after completing the activity.
Important Note – ACPE 60 Day Deadline:
Per ACPE requirements, CPE credit must be claimed within 60 days of being earned. To verify that you have completed the required steps and to ensure your credits have been reported to CPE Monitor, check your NABP eProfile account to validate that your credits were transferred successfully before the ACPE 60-day deadline. After the 60-day deadline, ASHP will no longer be able to award credit for this activity.
The ASHP Professional Certificates SM educational product line contains learning activities that are ACPE-accredited knowledge and application-based continuing education. This is not an ACPE Certificate Program. Upon successful completion of the activities, the learner will be able to download an ASHP Professional Certificate.
System Technical Requirements
ASHP learning content is delivered through your Web browser. For all learning content, you will need basic computer skills, the ability to navigate web pages and stable internet connection. View the system requirements for learning activities.